J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

Novo Nordisk's weight loss drug, Saxenda, helped children ages six to 11 reduce their body mass index in a recent trial.

Novo Nordisk (NVO) had temporarily shifted some of its production capacity away from its other diabetes drug, Victoza, to increase the supply of Ozempic. Its latest note said that although Victoza ...

Late last year, Novo Nordisk responded to a growing shortage ... the EMA said. If neither drug is available for patients currently using the meds, patients should be switched to another injectable ...

In conversation with experts, we’ll break down what you need to know about the most commonly prescribed type of contraception in the United States: the pill. “The most common and most familiar ...

Since the days of Abraham — who, according to Genesis, rescued his nephew Lot after he’d been seized by an invading army — Jewish tradition has placed supreme value on the redemption of ...

GMRx2, a new combination pill for hypertension, was found to be more effective than standard care in reducing blood pressure. The pill showed impressive results, achieving blood pressure control in ...

Sept 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected ...

Opens in a new tab or window LONDON -- Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to stenting from the start, the REC ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...